News | Stents | March 24, 2016

NIRTRAKS Study of Novel Coronary Stent Enrolls First Patient

Data will be collected from 131 patients across eight U.S. sites

Medinol, NIRTRAKS Study, NIRxcell Stent System, first patient

Image courtesy of Medinol

March 24, 2016 — Medinol announced the enrollment of their first patient in the U.S. NIRTRAKS Study. NIRTRAKS is a post marketing, non-randomized study of the NIRxcell Stent System in patients with coronary artery disease indicated for percutaneous coronary intervention (PCI). 

The study objective is to collect and analyze additional information about the safety and effectiveness of the NIRxcell stent in the treatment of de novo lesions in native coronary arteries in the U.S. population. The data will be collected from 131 patients with a primary endpoint of target vessel failure (TVF) at three years.  Manesh Patel, M.D., Duke University Hospital, is the national principal investigator (PI) for the study with a total of eight sites participating across the United States.  

"We are pleased with the start of the NIRTRAKS study, allowing us to gather further data on this unique and highly innovative technology.  While we have been utilizing the NIRxcell commercially for the last nine months, we are excited to further understand the clinical application this new design has for our patients," said Patel.

The first patient was enrolled into the study on Jan. 15, and over the last few weeks, site enrollment has continued to increase.

The NIRTRAKS study will look to build on the results of the PIONIR prospective study, which saw the NIRxcell stent demonstrate a 5.1 percent target lesion revascularization (TLR) rate at nine months, according to Medinol’s Chief Scientific Officer Yoram Richter, Ph.D.

The NIRxcell Stent is Medinol's fifth-generation coronary stent. It features the WiZeCell stent design, offering an optimal balance between vessel conformability, scaffolding integrity and radial strength.  The Flexx2 delivery system with a spring tip ensures ease of delivery even in the most tortuous and calcified anatomies.  NIRxcell became commercially available in the United States in January 2015.

NIRxcell Stent technology serves as a platform for Medinol's eDES (elastomer drug-eluting stent) currently in clinical trials in the U.S., Canada, Europe and Israel.

For more information: www.medinol.com

Related Content

Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Overlay Init